In the present study, we examined a role of mitogen-activated protein 
Introduction
Peroxisome proliferator-activated receptor (PPAR ) is a member of the nuclear receptor superfamily that includes receptors for steroids, thyroid hormone, vitamin D and retinoic acid [1] . PPAR is expressed at high levels in adipose tissue and functions as a key molecule of adipocyte differentiation [2, 3] . In addition to adipose tissue, PPAR expression is detected in a wide variety of tumor cells [4 -13] . In the tumor cells, PPAR activation by its high affinity ligands could inhibit cell growth and induce apoptosis. Thus PPAR is involved in not only lipid metabolism but also cellular proliferation in cancer cells. It is therefore suggested that PPAR is considered as a possible molecular target for cancer treatment.
With regard to the mechanism by which PPAR activation by its ligands induces growth arrest and apoptosis, we have already demonstrated that protein accumulation of p27 Kip1 , a cyclin-dependent kinase inhibitor (CDKI) [14, 15] , and p53 play a role in the growth arrest and apoptosis in human pancreatic and gastric cancer cells [16] [17] [18] . However, little is known whether other molecules that regulate cell proliferation and apoptosis are involved in the cellular behavior evoked by PPAR ligands such as troglitazone.
Mitogen-activated protein kinases (MAPKs) are essential components of the intracellular signal transduction pathways that regulate cell proliferation and apoptosis [19] [20] [21] . There are three subgroups of MAPKs, extracellular signal releted kinases (ERKs), c-Jun N-terminal protein linases (JNKs) and p38 MAPKs. For instance, activation of ERK culminates in phosphorylation of transcription factors responsible for regulating genes that enhance cell proliferation and protect cells from apoptosis [22, 23] . In the present study, we examined the hypothesis that MAPKs may be involved in the mechanism by which troglitazone inhibits cell growth in human pancreatic cancer cells.
Materials and Methods

Cell culture
Human pancreatic cancer cell line, PK-1 [24] was obtained from Tohoku University, Sendai, Japan. Our previous study confirmed PK-1 cells express PPAR  . The pancreatic cancer cells were cultured in RPMI-6 1640 medium (GIBCO, Grand Island, NY) supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 2.5 µg/ml amphotericine, and 10 % fetal bovine serum. Cells were incubated at 37 o C in a humidified atmosphere of following the manufacturer's suggested procedure. Normal rabbit IgG was used simultaneously as a control.
Cell Growth Assay
Cell number was evaluated by WST-1 assay according to our previous reports [16, 28] . Cells were seeded on a 96 well cell culture cluster (Corning U0126 or PD98059 at several concentrations for 0 or 48 hours. Cell numbers were measured colorimetrically using the Cell Counting Kit (Dojindo, Kumamoto, Japan) by ImmunoMini NJ-2300 (NJ InterMed, Tokyo, Japan) at a test wavelength of 450 nm. This assay is based on the cleavage of the 2-(4-
monosodium salt (WST-1) by mitochondrial dehydrogenase in viable cells [29] .
Statistical analysis
The results are expressed as mean ± SEM. Statistical analysis was performed by repeated measures ANOVA and subsequent Fisher's LSD test. P < 0.05 was considered statistically significant.
Results
Troglitazone inhibits ERK1/2 phosphorylation in human pancreatic cancer We, therefore, determined whether troglitazone inhibits ERK1/2 phosphorylation by inhibiting its upstream activator, MEK1/2. Like ERK1/2, MEK1/2 is activated by phosphorylation, and phospho-specific antibodies were used to assay MEK1/2 activity by western blotting. As shown in Figure   2A , performed to evaluate the effect of the chemicals on cell growth. As illustrated in Figure 4 , troglitazone dose-dependently inhibited cell growth, being in good agreement with our previous report [16] . It was also demonstrated that U0126 and PD98059 inhibited cell growth in a dosedependent fashion.
Discussion
We have already demonstrated that human pancreatic cancer cells express functional PPAR and PPAR activation by its specific ligands such as troglitazone induced cell growth arrest and inhibited cell invasion [16, 30] .
These results suggest that PPAR is a possible molecular target for pancreatic cancer treatment and PPAR ligands such as thiazolidinediones may be relevant for cancer therapy. There is however a little evidence about the molecular mechanisms by which troglitazone exerts its anti-proliferative action. Along this line, we have demonstrated that p27 Kip1 and p53 is implicated in the cytotoxicity by troglitazone in human pancreatic and gastric cancer cells [16, 17, 18, 28] . The present study was performed to try to 
